These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 32503608

  • 1. Efficacy and safety of YinQiSanHuang-antiviral decoction in chronic hepatitis B: study protocol for a randomized, placebo-controlled, double-blinded trial.
    Wu QJ, Lv WL, Li JM, Zhang TT, Zhou WH, Zhang Q, Wang JC, Wang QN, Zhang RX, Zhao X, Chen ST, Liu S, Li GH, Cao ZM, Xu L, Chen J.
    Trials; 2020 Jun 05; 21(1):482. PubMed ID: 32503608
    [Abstract] [Full Text] [Related]

  • 2. Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial.
    Qu J, Yu Z, Li Q, Chen Y, Xiang D, Tan L, Lei C, Bai W, Li H, Shang Q, Chen L, Hu X, Lu W, Li Z, Chen D, Wang X, Zhang C, Xiao G, Qi X, Chen J, Zhou L, Chen G, Li Y, Zeng Z, Rong G, Dong Z, Chen Y, Lou M, Wang C, Lu Y, Zhang C, Yang Y.
    Trials; 2014 Nov 10; 15():438. PubMed ID: 25381721
    [Abstract] [Full Text] [Related]

  • 3. Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial.
    Ye YA, Li XK, Zhou DQ, Chi XL, Li Q, Wang L, Lu BJ, Mao DW, Wu QK, Wang XB, Zhang MX, Xue JD, Li Y, Lu W, Guo JC, Jiang F, Zhang XW, Du HB, Yang XZ, Guo H, Gan DN, Li ZG.
    Chin J Integr Med; 2018 Sep 10; 24(9):653-660. PubMed ID: 30209792
    [Abstract] [Full Text] [Related]

  • 4. Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multicener, double-blind, randomized controlled trial in China.
    Li X, Zhang L, Qiu M, Huang Y, Xiao H, Lu B, Jiang Y, Long F, Lin H, He J, Wu Q, Zhang M, Wang L, Zhu X, Gong M, Sun X, Sun J, Sun F, Lu W, Xu W, Chen G, Li Z, Gan D, Yang X, Du H, Ye Y.
    Trials; 2020 Aug 12; 21(1):708. PubMed ID: 32787905
    [Abstract] [Full Text] [Related]

  • 5. YinQiSanHuang Jiedu decoction for the treatment of hepatitis B-related compensated liver cirrhosis: study protocol for a multi-center randomized controlled trial.
    Wu QJ, Lv WL, Li JM, Zhang TT, Zhou WH, Zhang Q, Wang JC, Wang QN, Yao ZA, Qiang R, Chen ST, Zhao X, Liu S, Cao ZM, Xu L, Li GH, Chen J, Wang L.
    Trials; 2021 Oct 14; 22(1):701. PubMed ID: 34649610
    [Abstract] [Full Text] [Related]

  • 6. Effect of Fufang Biejia Ruangan Tablet on lowering biochemical and virological parameters of hepatic fibrosis in patients with chronic hepatitis B: Protocol for a systematic review and meta-analysis of randomized controlled trials and cohort studies.
    Huang C, Shen D, Sun S, Huang Y, Xin Y, Luo H, Chen Y, Zhou Z, Liu F, Chen X.
    Medicine (Baltimore); 2019 Apr 14; 98(17):e15297. PubMed ID: 31027094
    [Abstract] [Full Text] [Related]

  • 7. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N, Xu JH, Yu M, Wang S, Si CW, Yu YY.
    World J Gastroenterol; 2015 Nov 21; 21(43):12421-9. PubMed ID: 26604649
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of entecavir in chronic hepatitis B patients with persistently normal alanine aminotransferase: randomized, double-blind, placebo-controlled study.
    Tseng KC, Chen CY, Tsai HW, Chang TT, Chuang WL, Hsu PI, Liu WC, Cheng PN.
    Antivir Ther; 2014 Nov 21; 19(8):755-64. PubMed ID: 24583931
    [Abstract] [Full Text] [Related]

  • 9. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
    Liu R, Guo J, Lu Y, Zhang L, Shen G, Wu S, Chang M, Hu L, Hao H, Li M, Xie Y.
    Clin Exp Med; 2019 Aug 21; 19(3):309-320. PubMed ID: 31111345
    [Abstract] [Full Text] [Related]

  • 10. Impact of Fuzheng Huayu tablet on antiviral effect of entecavir in patients with hepatitis B cirrhosis.
    Cheng DY, Zhao ZM, Wan G, Zheng HW, Huang JQ, Liu CH, Xing HC.
    Hepatobiliary Pancreat Dis Int; 2022 Oct 21; 21(5):479-484. PubMed ID: 35346577
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
    Yuan Y, Iloeje UH, Hay J, Saab S.
    J Manag Care Pharm; 2008 Oct 21; 14(1):21-33. PubMed ID: 18240879
    [Abstract] [Full Text] [Related]

  • 12. [Entecavir: a new hope for the treatment of chronic hepatitis B].
    Calleja JL, Peñas B.
    Gastroenterol Hepatol; 2007 May 21; 30(5):285-93. PubMed ID: 17493440
    [No Abstract] [Full Text] [Related]

  • 13. Meta-analysis of influences of Biejiajian Pill combined with entecavir on serum liver fibrosis markers of compensatory period of hepatitis b cirrhosis: Protocol of systematic review and meta-analysis.
    Zhang T, Yang Y, Wang B, Zheng X, Wang L, Feng X, Li G, Shi J, Cao N.
    Medicine (Baltimore); 2019 Dec 21; 98(51):e18458. PubMed ID: 31861022
    [Abstract] [Full Text] [Related]

  • 14. Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial.
    Li X, Zhou D, Chi X, Li Q, Wang L, Lu B, Mao D, Wu Q, Wang X, Zhang M, Xue J, Li Y, Lu W, Guo J, Jiang F, Zhang X, Li Z, Yang X, Guo H, Gan D, He L, Luo L, Zhang L, Du H, Ye Y.
    Hepatol Int; 2020 Dec 21; 14(6):985-996. PubMed ID: 33128206
    [Abstract] [Full Text] [Related]

  • 15. Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B.
    Jonas MM, Chang MH, Sokal E, Schwarz KB, Kelly D, Kim KM, Ling SC, Rosenthal P, Oraseanu D, Reynolds L, Thiry A, Ackerman P.
    Hepatology; 2016 Feb 21; 63(2):377-87. PubMed ID: 26223345
    [Abstract] [Full Text] [Related]

  • 16. Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B.
    Wang PC, Wei TY, Tseng TC, Lin HH, Wang CC.
    Eur J Gastroenterol Hepatol; 2017 Aug 21; 29(8):946-950. PubMed ID: 28538267
    [Abstract] [Full Text] [Related]

  • 17. Nucleoside analogs assisted with Chinese compound prescription in treating hepatic fibrosis of chronic hepatitis B patients: A protocol of systematic review and meta-analysis.
    Cheng M, Feng X, Wang L, Yang Y, Ma L, Wang B.
    Medicine (Baltimore); 2020 Jul 02; 99(27):e21032. PubMed ID: 32629728
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy and safety of Entecavir monotherapy switched from Lamivudine combined Adefovir Dipivoxil for chronic hepatitis B virus-related compensated liver cirrhosis].
    Lai XJ, Lian JS, Chen JY, Zhang YM, Jia HY, Zheng L, Yang YD.
    Zhonghua Gan Zang Bing Za Zhi; 2018 Feb 20; 26(2):113-118. PubMed ID: 29804377
    [Abstract] [Full Text] [Related]

  • 19. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH, Shi KQ, Dai ZJ, Ye C, Chen YP.
    Clin Ther; 2010 Apr 20; 32(4):649-58. PubMed ID: 20435234
    [Abstract] [Full Text] [Related]

  • 20. Treatment of HBV Cirrhosis with Fuzheng Huayu Tablet () and Entecavir: Design of a Randomized, Double-Blind, Parallel and Multicenter Clinical Trial.
    Li ZX, Zhao ZM, Liu P, Zheng QS, Liu CH.
    Chin J Integr Med; 2021 Jul 20; 27(7):509-513. PubMed ID: 32572776
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.